University of Florida registers pilot trial of low dose naltrexone for vulvodynia

This week's filing covers a single new registry record from University of Florida, the trial's lead sponsor, with Mayo Clinic listed as collaborator.

• "A Pilot Study on the Efficacy of Oral Low Dose Naltrexone for Vulvodynia" (NCT07862400) is an observational pilot study sponsored by University of Florida, with Mayo Clinic as collaborator, and is listed as not yet recruiting. The study's lead sponsor is University of Florida with Mayo Clinic as collaborator, and overall status is not yet recruiting.¹ The trial plans to enroll 20 women with vulvodynia who will take a 4-week course of 4.5 mg oral LDN daily¹, with primary outcomes measured by the Global Treatment Improvement Scale and secondary outcomes including NRS, CSI, and VPAQ scores¹. Estimated start is January 2027.